Meet the Researchers
View All-
Julie Wu, MD
Staff Physician, Medical Oncology
Precision oncology integrating evidence-based models into clinical practice to personalize treatment approaches
-
Jonathan Villena-Vargas, MD
Thoracic Surgeon
Characterizing T cell PD-1 response in the tumor-draining lymph nodes of early-stage NSCLC patients
-
Kellie Smith, PhD
Leading an immunology lab in transformative cancer research
Immunotherapy in Early Stage Lung Cancer
Recently diagnosed with lung cancer?
Learn more about your lung cancer diagnosis. What questions should you be asking? What are the most important next steps? Know that you have options and remember that knowledge is power.
Together we can make a lasting impact
Your support is vital to our mission of funding transformative science and improving survivorship.
Stay Connected
Hope, Research, and Impact in Your Inbox
Join our community and receive monthly updates on inspiring stories, groundbreaking research, and the early career researchers you’re helping to support. Sign up now to be part of the lung cancer fight!
-
Research is HOPE. Research will hopefully have me sitting here in #GiveMe20. Give me 20 years post-diagnosis.
Brandi Bryant, living with lung cancer
-
Your generosity is shaping future leaders in lung cancer research.
Kim Norris, Co-Founder and President
-
There is such tremendous hope for all patients with lung cancer right now.
Dr. Christine Lovly, LCFA Young Investigator
Word of the Day
STK11
STK11 is a mutation in the STK11 protein and is one biomarker that physicians look for in non-small cell lung cancer. STK11 was first discovered in 1996. Everyone has two STK11 genes (one from their mother and one from their father). If one of the genes is not working, this is known as having a faulty STK11 gene or having an STK11 mutation.